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Abstract An 88-year-old man, receiving pred-
nisolone for sarcoidosis, presented with a discrete
keratotic lesion on the dorsum of his right hand
following the placement of an intravenous cannula a
month prior to its appearance. Medicopsis romeroi
was isolated from the tissue and identified by
sequencing the internal transcribed spacer region
ITS-1 and the D1-2 fragment of the 28S rDNA gene.
Histopathological examination showed fungal hyphae
in the internal inflammatory cells layer and within the
histocyte-macrophage layer, highly suggestive of deep
mycosis. The patient was successfully treated with
surgical excision of the cyst. M. romeroi exhibited
high MIC values for echinocandin drugs in vitro, but
appeared susceptible to newer triazole agents, ampho-
tericin B and terbinafine. This is the first report of a
subcutaneous phaeohyphomycotic cyst occurring
following the placement of an intravenous cannula.
This report highlights the potential role of M. romeroi
as an emerging cause of deep, non-mycetomatous
infection in immunocompromised patients.
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Introduction
Phaeohyphomycoses are fungal infections of the skin,
or internal organs, caused by darkly pigmented,
melanized fungi, which are widely distributed in the
environment [1]. In recent years, the incidence of
A. Abdolrasouli (&)  X. Gonzalo  B. S. Azadian
Department of Medical Microbiology, 4th Floor East
Wing Laboratory Block, Charing Cross Hospital, Imperial
College Healthcare NHS Trust, Fulham Palace Road,
London W6 8RF, UK
e-mail: ali_reza878@yahoo.com
A. Abdolrasouli
Fungal Pathogens Immunobiology Laboratory, National
Heart and Lung Institute, Imperial College London,
London, UK
N. Francis
Department of Pathology, Charing Cross Hospital,
Imperial College Healthcare NHS Trust, London, UK
A. Jatan  G. J. McArthur
Department of Plastic Surgery, Chelsea and Westminster
Hospital, Chelsea and Westminster NHS Foundation
Trust, London, UK
A. M. Borman  E. M. Johnson
National Mycology Reference Laboratory and National
Collection of Pathogenic Fungi, Public Health England,
Bristol, UK
123
Mycopathologia
DOI 10.1007/s11046-016-0017-4
phaeohyphomycosis as well as the diversity of
causative organisms has been reported to be increasing
globally [2]. Clinically, they are involved in diseases
ranging from mild, superficial infections [3] to fatal
cerebral phaeohyphomycosis in otherwise healthy
individuals [4].
Subcutaneous phaeohyphomycoses is an uncom-
mon localised fungal infection of the deep dermis and
subcutaneous tissues caused by a heterogeneous group
of dematiaceous fungi [5]. Infection is thought to
result from traumatic implantation of the causative
fungal organism into the subcutaneous tissue. This
form of infection is more common in warm climates
and has been reported mainly in immunocompromised
hosts [6]. It commonly presents as a single, well-
encapsulated, subcutaneous mass or a nodule at the
site of previous trauma, commonly on the extremities.
The common causative organisms reported include
Exophiala, Alternaria, Phialophora, Cladophialo-
phora, and Curvularia/Bipolaris species [5, 7]; how-
ever, many others have been implicated on occasion
[8, 9].
Medicopsis romeroi, formerly known as Pyreno-
chaeta romeroi, is a rare agent of human black-grain
eumycetoma [10, 11]. Recently M. romeroi emerged
as a cause of deep, non-mycetomatous infections
mainly in immunocompromised patients [12–19]. We
report here a case of subcutaneous phaeohyphomy-
cotic cyst of the hand caused by M. romeroi in an
immunocompromised man.
Case Report
In July 2015, an 88-year-old British man of mixed
heritage (Caucasian and Afro-Caribbean) but resident
in England most of his life, presented with a 5-month
history of a discrete keratotic lesion on the dorsum of
his right hand, following the placement of an intra-
venous cannula a month prior to its appearance. His
medical history included chronic obstructive pul-
monary disease, gout, benign prostatic hyperplasia,
deep venous thrombosis, sarcoidosis and linear IgA
dermatosis. He was on multiple medications for his
comorbidities, among which was the immunosuppres-
sant prednisolone. He was treated for leprosy and
Bell’s palsy in 1994 and denied any recent overseas
travel.
Examination confirmed a necrotic lesion
20 9 12 mm with a 3 9 3 mm well-circumscribed
whitened area. The lesion was confined to the skin and
subcutaneous tissue with no extension to extensor
tendons, bone, lymph node or neurovascular involve-
ment. Cellulitis, tracking lymphangitis and regional
lymphadenopathy were absent.
With a differential diagnosis of atypical abscess and
epidermal inclusion cyst, the cyst was removed by
elliptical excision to subcutis with primary closure; the
patient received co-amoxiclav and co-codamol upon
discharge. In 10 days of follow up, there was no sign of
infection. Histological examination showed an
abscess with central neutrophils and prominent sur-
rounding infiltrate of epithelioid macrophages with
some giant cells. Periodic acid-Schiff stain showed
fungal hyphae in the internal inflammatory cells layer
and within the histocyte-macrophage layer (Fig. 1),
highly suggestive of deep mycosis. Microscopic
examination of the tissue sample with calcofluor white
revealed fungal elements, but no granules were
observed macroscopically. A dematiaceous mould
grew after 10 days of incubation on Sabouraud
dextrose agar at both 30 and 37 C (Fig. 2). Micro-
scopic examination of the culture showed broad,
septate, branched and dark brown hyphae consistent
with dematiaceous fungi. No conidia were observed
(Fig. 3). With the diagnosis of phaeohyphomycotic
cyst, and in view of our patient’s immunocompro-
mised state, he was contacted to offer antifungal
therapy, which was refused.
For species identification, the internal transcribed
spacer region ITS-1 and the D1-2 fragment of the 28S
rDNA gene were amplified by PCR using extracted
DNA and panfungal primers using previously estab-
lished protocols [20, 21]. The sequences of the
resulting amplicons (European Molecular Biology
Laboratory (EMBL) accession nos. LN999520 and
LN999521) were both 100 % identical to reference
sequences of M. romeroi present in public sequence
databases, and to the type strain of M. romeroi in the
National Collection of Pathogenic Fungi (NCPF 2301)
housed at the National Mycology Reference Labora-
tory, Public Health England, Bristol, UK (data not
shown). The isolate from the current case has been
preserved in inert form in the NCPF with the unique
identifier NCPF 7881.
Antifungal susceptibility testing was performed by
microbroth dilution according to the Clinical and
Laboratory Standards Institute (CLSI) M38-A2 guide-
line [22]. The minimum inhibitory concentrations
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(MICs) of antifungal drugs were: amphotericin B
(0.25 lg/ml), fluconazole ([64 lg/ml), itraconazole
(0.5 lg/ml), voriconazole (0.5 lg/ml), posaconazole
(0.25 lg/ml) and terbinafine (0.125 lg/ml). Caspo-
fungin, anidulafungin and micafungin all gave mini-
mum effective concentration (MEC) of 4.0 lg/ml.
Discussion
Phaeohyphomycosis is an uncommon fungal infec-
tion, although its incidence has been reported to be on
the rise globally [1, 2]. Most phaeohyphomycosis
infections are caused by Exophiala, Alternaria,
Cladophialophora, Phialophora or Curvularia/Bipo-
laris species; however, many others have been impli-
cated on occasion [5, 7]. Infection is most often
Fig. 1 Fungal hyphae in the internal inflammatory cells layer and within the histocyte-macrophage layer, PAS stain with magnification
of 9200 (a) and 9400 (b)
Fig. 2 Colonies of M. romeroi on SDA (a), and malt extract agar (b) after 10 days incubation at 28–30 C in dark. Colonies were
initially brownish but became olivaceous grey and floccose with age on both culture media
Fig. 3 Broad, septate, branched and dark brown hyphae
consistent with dematiaceous fungi. Magnification 9400
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acquired from traumatic implantation of the causative
agent into subcutaneous tissue. The usual clinical
presentation is the asymptomatic development of a
single subcutaneous mass (nodule, cyst or abscess) at
the site of prior trauma [6].M. romeroi is a saprophytic
fungus widely distributed worldwide, where it grows
on soil and vegetation, particularly in tropical cli-
mates. The majority of the previously reported cases
have occurred in patients with a history of residence in
India, Pakistan and Venezuela [12].
Although the etiological role of M. romeroi in
black-grain mycetoma is well established [10, 23], it
has only recently been recognised as a cause of deep,
non-mycetomatous infections [12–17, 19]. In contrast
to mycetoma, no discharge or visible grains are
present. This could potentially be a relatively new
clinical condition presenting as subcutaneous nodule,
cyst or abscess caused by this species mostly in
immunocompromised patients. Our patient was on
long-term prednisolone for sarcoidosis which we
believe could potentially contribute to his recent
fungal infection with M. romeroi. Among the
immunosuppressed population, solid organ transplant
recipients and patients receiving chronic corticos-
teroids are at risk for dematiaceous fungal infections
[6, 24, 25]. Of note, most cases of subcutaneous
phaeohyphomycosis caused by M. romeri have been
reported among renal transplant recipients [15, 17, 19,
26]. Individual cases have also been described in
patients with acute lymphoblastic leukaemia [13],
diabetes mellitus [14] or those receiving prolonged
immunosuppressant agents [16, 18]. However, cases
have been described in previously healthy immuno-
competent individuals [12] where cysts are often
chronic and relatively asymptomatic.
Subcutaneous phaeohyphomycotic lesions are
often surgically excised which is usually curative
with no further antifungal therapy [12, 27]. Systemic
antifungal therapy is used in patients with refractory or
recurrent infections perhaps due to incomplete resec-
tion of the lesion. The agents that have most frequently
been used include amphotericin B, 5-flucytosine,
itraconazole and terbinafine. The newer triazoles have
moderate-to-excellent in vitro antifungal activity
against dematiaceous moulds and can be given safely
for prolonged periods for treatment of phaeohyphumy-
cosis [27].
Information on the antifungal susceptibility of M.
romeroi is rather limited due to lack of high number of
clinical isolates and absence of established break-
points. In addition, relation between in vitro MIC
values and clinical outcome of infection is poorly
understood. The available evidence suggests consid-
erable strain-specific variation in MIC values with
respect to amphotericin B and itraconazole, elevated
MICs for fluconazole, ketoconazole, and lower MICs
for voriconazole [23, 28]. Our isolate demonstrated a
high MIC with fluconazole; however, lower MICs
were observed to the newer triazole agents. High
MECs observed with the echinocandin group, in
agreement with previous reports [23, 28], suggest
these agents would not be a good choice for treatment
of M. romeroi infections. Terbinafine might be
efficacious against this fungus.
Conclusion
This report highlights the potential role of M. romeroi
as an emerging cause of subcutaneous, phaeohy-
phomycotic cysts in immunocompromised patients
with no travel history to tropical or subtropical areas.
Recognition of infections caused by dematiaceous
fungi remains challenging as many isolates are
difficult to identify by conventional methods and
require molecular approaches.
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